Richard T Silver - CML - Chronic myeloid leukemia
Throughout his distinguished career, Dr. Silver has remained at the forefront of research and clinical advances for the treatment of leukemia, and by the 1990s, he was appointed Chair of the Chronic Myeloid Leukemia (CML) Guidelines Committee of the American Society of Hematology. In 2004, the European LeukemiaNet recognized Dr. Silver’s “integrative and successful leadership” with an appointment to the ELN’s panel for management and recommendations on CML.
Extract of Dr. Silver Receives 2019 ELN Merit Award at the 16th European LeukemiaNet Symposium
Dr. Silver was one of the first physicians to use the anti-viral agent interferon in the treatment of chronic myeloid leukemia and the first to report its effectiveness against polycythemia vera. He developed courses to train physicians in the biopsy of bone marrow and interpretation of the results. His research contributed significantly to current understandings of how infections develop in leukemia.
Extract of Cancer Research & Treatment Fund (CR&T)